Please provide your email address to receive an email when new articles are posted on . At 52 weeks, MASH resolution without worsening of fibrosis was reported among 36% on denifanstat vs. 13% on ...

A Poster of Distinction titled “Denifanstat elicited a significant ≥2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: ...

Adult patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or advanced liver fibrosis showed improved liver histology with a once-weekly dose of semaglutide (Wegovy), an ...

Resmetirom effectively resolves MASH and improves fibrosis, independent of GLP-1 or SGLT2 inhibitor use, in patients with T2DM. Achieving ≥5% weight loss enhances resmetirom's effects on MASH ...

Please provide your email address to receive an email when new articles are posted on . Among patients with FIB-4 nonalcoholic steatohepatitis at greater risk for progression to end stage liver ...

Efruxifermin significantly reduced both overall fibrosis and septal area in adults with metabolic dysfunction-associated steatohepatitis (MASH) and compensated cirrhosis, based on a post hoc analysis ...

The inherited progressive disorder cystic fibrosis (CF) causes severe damage to the lungs, and other tissues in the body by affecting the cells that produce mucus, sweat, and digestive juices. In ...

Background Interstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells but typically regarded as ...

Camilla Bell, M.Sc., Ph.D., an assistant professor in the UAB Department of Pathology’s Division of Molecular and Cellular Pathology, has been awarded a grant by Vertex Pharmaceuticals as part of the ...

Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.